Shanghai Raas
VerifiedA leading domestic blood product company integrating raw plasma collection, blood product R&D, production and sales.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$6.3b (Public information from Jun 2024)
Share price
CNY7.67 002252.SZ
Minhang District Shanghai (HQ)
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 7 % | 55 % | 53 % | 21 % | 14 % | 13 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 44 % | 65 % | 49 % | 41 % | 31 % | 32 % | 32 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 24 % | 48 % | 30 % | 29 % | 22 % | 28 % | 28 % |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 5 % | 3 % | 2 % | 2 % | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
* | €1.6b Valuation: €8.0b 9.7x EV/LTM Revenues 23.9x EV/LTM EBITDA | Secondary | |
| Total Funding | 000k | ||